Compare FRTT & QNME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRTT | QNME |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Integrated Freight & Logistics |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1M | 14.1M |
| IPO Year | 2025 | 2024 |
| Metric | FRTT | QNME |
|---|---|---|
| Price | $0.48 | $0.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.2M | 4.1M |
| Earning Date | 11-14-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.83 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,850,681.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 111.79 |
| 52 Week Low | $0.50 | $0.26 |
| 52 Week High | $3.92 | $1.40 |
| Indicator | FRTT | QNME |
|---|---|---|
| Relative Strength Index (RSI) | 28.08 | 44.19 |
| Support Level | N/A | $0.29 |
| Resistance Level | $1.03 | $0.43 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 1.99 | 19.80 |
Fort Technology Inc is engaged the identification and evaluation of assets or business with a view to potentially acquire them or an interest therein by an option or any concomitant transaction.
Quanome Technologies Inc operates in the midstream segment of the pharmaceutical industrial ecosystem, operating between upstream pharmaceutical manufacturers and downstream medical end customers. It sources products from multiple manufacturers and suppliers, and distribute them to hospitals, pharmaceutical distributors and other healthcare providers. Its principal product categories include infusion products, foods for special medical purposes, and specialty pharmaceuticals. It operates in one reportable segment serves its customers by providing pharmaceutical products in China. The company generates a substantial percentage of its revenue from selling pharmaceutical products on a direct basis.